Clearmind Advances AUD Trial After Positive Safety Data
Event summary
- Clearmind's Phase I/IIa trial for CMND-100 in Alcohol Use Disorder (AUD) advances to third cohort after DSMB approval.
- Second cohort showed favorable safety profile at double the dose of first cohort, with no serious adverse events.
- Trial conducted across Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
- Third cohort will test 80 mg per administration, double the second cohort's dose.
The big picture
Clearmind's progress reflects growing interest in psychedelic-derived therapies for addiction treatment. The trial's multinational structure underscores both regulatory confidence and the need for innovative solutions in addressing Alcohol Use Disorder, a condition with significant unmet medical needs. Success here could position CMND-100 as a potential first-mover in this emerging therapeutic category.
What we're watching
- Dose Escalation
- Whether the safety profile holds at higher doses in the third cohort.
- Trial Momentum
- The pace at which Clearmind can progress through subsequent trial phases.
- Competitive Positioning
- How CMND-100's non-hallucinogenic profile differentiates it in the AUD treatment landscape.
Related topics